Business Description
Cosmo Pharmaceuticals NV
ISIN : NL0011832936
Share Class Description:
CHIX:COPNz: Registered SharesDescription
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 27.34 | |||||
Equity-to-Asset | 0.76 | |||||
Debt-to-EBITDA | 0.07 | |||||
Interest Coverage | 0.85 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 6.87 | |||||
Beneish M-Score | -2.89 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 6.1 | |||||
3-Year EBITDA Growth Rate | 34.5 | |||||
3-Year EPS without NRI Growth Rate | 19 | |||||
3-Year FCF Growth Rate | 43.1 | |||||
3-Year Book Growth Rate | -6.1 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 22.71 | |||||
9-Day RSI | 35.27 | |||||
14-Day RSI | 41.68 | |||||
6-1 Month Momentum % | 40 | |||||
12-1 Month Momentum % | 53.1 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.98 | |||||
Quick Ratio | 3.42 | |||||
Cash Ratio | 1.96 | |||||
Days Inventory | 250.66 | |||||
Days Sales Outstanding | 121.8 | |||||
Days Payable | 175.26 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 2.8 | |||||
Forward Dividend Yield % | 2.8 | |||||
5-Year Yield-on-Cost % | 2.8 | |||||
3-Year Average Share Buyback Ratio | -3.6 | |||||
Shareholder Yield % | 11.27 |
Profitability Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 79.33 | |||||
Operating Margin % | 7.86 | |||||
Net Margin % | -5.18 | |||||
FCF Margin % | 19.72 | |||||
ROE % | -1.09 | |||||
ROA % | -0.69 | |||||
ROIC % | -3.46 | |||||
ROC (Joel Greenblatt) % | 17.46 | |||||
ROCE % | 1.85 | |||||
Years of Profitability over Past 10-Year | 5 |
GF Value Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 10.41 | |||||
Shiller PE Ratio | 27.76 | |||||
PS Ratio | 12.89 | |||||
PB Ratio | 2.87 | |||||
Price-to-Tangible-Book | 41.41 | |||||
Price-to-Free-Cash-Flow | 65.38 | |||||
Price-to-Operating-Cash-Flow | 35.6 | |||||
EV-to-EBIT | 111.13 | |||||
EV-to-Forward-EBIT | 26.86 | |||||
EV-to-EBITDA | 46.26 | |||||
EV-to-Forward-EBITDA | 18.18 | |||||
EV-to-Revenue | 12.2 | |||||
EV-to-Forward-Revenue | 4.38 | |||||
EV-to-FCF | 63.35 | |||||
Price-to-Projected-FCF | 4.45 | |||||
Price-to-Median-PS-Value | 0.67 | |||||
Earnings Yield (Greenblatt) % | 0.9 | |||||
FCF Yield % | 1.56 | |||||
Forward Rate of Return (Yacktman) % | 21.21 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cosmo Pharmaceuticals NV Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil CHF) | 88.915 | ||
EPS (TTM) (CHF) | -0.285 | ||
Beta | 1.43 | ||
Volatility % | 47.01 | ||
14-Day RSI | 41.68 | ||
14-Day ATR (CHF) | 1.35046 | ||
20-Day SMA (CHF) | 72 | ||
12-1 Month Momentum % | 53.1 | ||
52-Week Range (CHF) | 33.85 - 75.8 | ||
Shares Outstanding (Mil) | 16.05 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Cosmo Pharmaceuticals NV Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Cosmo Pharmaceuticals NV Stock Events
Event | Date | Price(CHF) | ||
---|---|---|---|---|
No Event Data |
Cosmo Pharmaceuticals NV Frequently Asked Questions
What is Cosmo Pharmaceuticals NV(CHIX:COPNz)'s stock price today?
The current price of CHIX:COPNz is CHF70.40. The 52 week high of CHIX:COPNz is CHF75.80 and 52 week low is CHF33.85.
When is next earnings date of Cosmo Pharmaceuticals NV(CHIX:COPNz)?
The next earnings date of Cosmo Pharmaceuticals NV(CHIX:COPNz) is .
Does Cosmo Pharmaceuticals NV(CHIX:COPNz) pay dividends? If so, how much?
The Dividend Yield %  of Cosmo Pharmaceuticals NV(CHIX:COPNz) is 2.8% (As of Today), Highest Dividend Payout Ratio of Cosmo Pharmaceuticals NV(CHIX:COPNz) was 1.1. The lowest was 0.81. And the median was 0.91. The  Forward Dividend Yield % of Cosmo Pharmaceuticals NV(CHIX:COPNz) is 2.8%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |